15,141 Shares in Danaher Corporation $DHR Purchased by Annex Advisory Services LLC

Key Points

• Annex Advisory Services opened a new position in Danaher, buying 15,141 shares worth about $3.47 million, while institutional investors collectively own about 79.05% of the company.
• Danaher beat Q4 expectations with $2.23 EPS (vs. $2.14 est.) and revenue of $6.84 billion (up 4.6% YoY), and the board raised the quarterly dividend to $0.40 (annualized $1.60, 0.8% yield).
• Several analysts trimmed price targets this week (e.g., TD Cowen, Goldman, Wolfe), reducing implied upside, but consensus remains a Moderate Buy with an average target of about $247.35; the stock trades near $198.58 within a 52-week range of $180.03–$242.80.

Annex Advisory Services LLC acquired a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 15,141 shares of the conglomerate's stock, valued at approximately $3,466,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. JPL Wealth Management LLC bought a new position in Danaher in the 3rd quarter worth about $25,000. WFA of San Diego LLC bought a new position in Danaher in the 2nd quarter worth about $26,000. ANTIPODES PARTNERS Ltd bought a new position in Danaher in the 3rd quarter worth about $27,000. TruNorth Capital Management LLC bought a new position in Danaher in the 3rd quarter worth about $28,000. Finally, Tripletail Wealth Management LLC bought a new position in Danaher in the 3rd quarter worth about $31,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Stock Up 1.4%

DHR stock opened at $198.58 on Wednesday. Danaher Corporation has a 12 month low of $180.03 and a 12 month high of $242.80. The firm has a market cap of $140.54 billion, a PE ratio of 39.40, a P/E/G ratio of 2.66 and a beta of 0.95. The firm has a 50 day simple moving average of $200.12 and a 200 day simple moving average of $214.88. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.87 and a quick ratio of 1.51.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, January 27th. The conglomerate reported $2.23 EPS for the quarter, beating the consensus estimate of $2.14 by $0.09. Danaher had a net margin of 14.71% and a return on equity of 10.81%. The business had revenue of $6.84 billion during the quarter, compared to analyst estimates of $6.79 billion. During the same period in the prior year, the business earned $2.14 earnings per share. The business's quarterly revenue was up 4.6% on a year-over-year basis. Equities research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Investors of record on Friday, March 27th will be given a $0.40 dividend. This is a boost from Danaher's previous quarterly dividend of $0.32. The ex-dividend date is Friday, March 27th. This represents a $1.60 annualized dividend and a dividend yield of 0.8%. Danaher's payout ratio is currently 31.75%.

Analysts Set New Price Targets

Several research firms have commented on DHR. TD Cowen decreased their target price on shares of Danaher from $270.00 to $245.00 and set a "buy" rating for the company in a research report on Monday. KeyCorp reiterated an "overweight" rating on shares of Danaher in a report on Thursday, January 29th. Argus set a $265.00 price objective on shares of Danaher in a report on Wednesday, January 14th. The Goldman Sachs Group decreased their price objective on shares of Danaher from $265.00 to $230.00 and set a "buy" rating for the company in a report on Monday. Finally, Wolfe Research decreased their price objective on shares of Danaher from $260.00 to $230.00 and set an "outperform" rating for the company in a report on Wednesday, April 8th. Eighteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, Danaher has an average rating of "Moderate Buy" and a consensus target price of $247.35.

Insider Activity at Danaher

In related news, EVP Gregory M. Milosevich sold 1,320 shares of the company's stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $208.01, for a total value of $274,573.20. Following the completion of the sale, the executive vice president owned 5,099 shares in the company, valued at approximately $1,060,642.99. This represents a 20.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.80% of the company's stock.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Beckman Coulter Diagnostics (a Danaher unit) received CE mark for the Access MeMed BV assay, a high-throughput host‑response test that differentiates bacterial vs. viral infections in ~20 minutes — a commercial approval that could support diagnostics revenue and adoption in Europe. Beckman Coulter Diagnostics Earns CE Mark
• Positive Sentiment: Sector tailwind: cell therapy and regenerative medicine markets are forecast to grow strongly (high single- to double-digit CAGR), supporting long-term demand for life-science tools and services that benefit parts of Danaher’s portfolio. Cell Therapy Market Growth
• Neutral Sentiment: Danaher confirmed an upcoming earnings release next Tuesday — investors will focus on revenue growth, margin commentary and guidance for reaction. Danaher to Release Earnings
• Neutral Sentiment: Market commentary pieces are tracking recent share moves and volume, but contain no new material company guidance — useful for sentiment context but not new fundamentals. Share Price Commentary
• Negative Sentiment: Analysts trimmed price targets this week: TD Cowen cut its target to $245 (from $270) but kept a Buy rating, and Goldman lowered its target to $230 (from $265) while also retaining Buy — lower targets reduce implied upside even if convictions remain. TD Cowen Adjusts Price Target Goldman Target Cut
• Negative Sentiment: Pre-earnings analyst commentary (Zacks/Yahoo) suggests Danaher lacks the setup that typically yields an earnings beat in the coming report — if results or guidance disappoint, the stock could underperform near term. Earnings Beat Odds

Danaher Company Profile

Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.